埃萬妥單抗

埃萬妥單抗
	埃萬妥單抗的抗MET（英语：hepatocyte growth factor receptor）臂端（藍）與人的信号素結構域（英语：hepatocyte growth factor receptor）（紫褐色（英语：puce））結合的空間填充模型。PDB 6wvz
单克隆抗体
种类	完整抗体
目標	表皮生长因子受体 (EGFR) 和上皮間質轉化（英语：Mesenchymal–epithelial transition） (MET)
臨床資料
商品名（英语：Drug nomenclature）	Rybrevant
其他名稱	JNJ-61186372, amivantamab-vmjw
AHFS/Drugs.com	Monograph
MedlinePlus	a621034
核准狀況	美 DailyMed: Amivantamab;
懷孕分級	澳: D ; ;
给药途径	靜脈注射
藥物類別	化学疗法
ATC碼	L01FX18 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 加：处方药（℞-only）/ Schedule D; 歐：Rx-only; 美：处方药（℞-only）;
识别信息
CAS号	2171511-58-1
DrugBank	DB16695;
UNII	0JSR7Z0NB6;
KEGG	D11894;
化学信息
化学式	C6472H10014N1730O2023S46
摩尔质量	145,902.15 g·mol−1

埃萬妥單抗（INN：Amivantamab）用于治疗非小細胞肺癌（英语：Non-small-cell lung cancer）^[8] ^[9]。特別是針對表皮生长因子受体（EGFR）外显子20處插入突变，且其他治疗无效的晚期患者^[8]。通过静脉注射给药^[8]。

常见副作用包括皮疹、输液反应、指甲周围感染、肌肉和关节疼痛、呼吸短促、恶心、疲倦、肿胀、口腔溃疡、咳嗽和便秘^[8]。其他副作用可能包括肺炎、眼部问题、低钾、高血糖、低钠和肝脏炎症^[8]。孕期使用可能對婴儿有害^[8]。它是一种雙特異性單株抗體（英语：Bispecific monoclonal antibody），可与表皮生长因子（EGF）受体和上皮間質轉化（英语：Mesenchymal–epithelial transition）（MET）受体结合^[8]。

埃萬妥單抗于2021年在美国和欧洲取得医疗使用許可^[8] ^[9]。

参考文獻

^ ^1.0 ^1.1 Rybrevant (Janssen-Cilag Pty Ltd). Therapeutic Goods Administration (TGA). 13 January 2023 [18 April 2023]. （原始内容存档于27 March 2023）.
^ Rybrevant Product information. Health Canada. 25 April 2012 [29 June 2022]. （原始内容存档于29 June 2022）.
^ Summary Basis of Decision - Rybrevant. Health Canada. 23 October 2014 [6 August 2022]. （原始内容存档于6 August 2022）.
^ Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. （原始内容存档于26 May 2021）.
^ FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer. U.S. Food and Drug Administration (FDA) (新闻稿). 21 May 2021 [21 May 2021]. （原始内容存档于21 May 2021）. 本文含有此來源中屬於公有领域的内容。
^ FDA grants accelerated approval to amivantamab-vmjw for mNSCLC. U.S. Food and Drug Administration (FDA). 21 May 2021 [21 May 2021]. （原始内容存档于22 May 2021）. 本文含有此來源中屬於公有领域的内容。
^ Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. （原始内容存档于23 April 2022）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ^8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 ^8.6 ^8.7 Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. （原始内容存档于26 May 2021）.
^ ^9.0 ^9.1 Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. （原始内容存档于23 April 2022）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

延伸閱讀

Neijssen J, Cardoso RM, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PW, Strohl WR, Chiu ML. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. The Journal of Biological Chemistry //www.ncbi.nlm.nih.gov/pmc/articles/PMC8113745 |PMC=缺少标题 (帮助). April 2021, 296: 100641. PMC 8113745 . PMID 33839159. doi:10.1016/j.jbc.2021.100641 .
Yun J, Lee SH, Kim SY, Jeong SY, Kim JH, Pyo KH, Park CW, Heo SG, Yun MR, Lim S, Lim SM, Hong MH, Kim HR, Thayu M, Curtin JC, Knoblauch RE, Lorenzi MV, Roshak A, Cho BC. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discovery. August 2020, 10 (8): 1194–1209. PMID 32414908. doi:10.1158/2159-8290.CD-20-0116 .

外部連結

Clinical trial number NCT02609776 for "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)" at ClinicalTrials.gov

[Rybrevant_APMDS-1] 1.0 ^1.1 Rybrevant (Janssen-Cilag Pty Ltd). Therapeutic Goods Administration (TGA). 13 January 2023 [18 April 2023]. （原始内容存档于27 March 2023）.

[2] Rybrevant Product information. Health Canada. 25 April 2012 [29 June 2022]. （原始内容存档于29 June 2022）.

[3] Summary Basis of Decision - Rybrevant. Health Canada. 23 October 2014 [6 August 2022]. （原始内容存档于6 August 2022）.

[Rybrevant_FDA_label-4] Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. （原始内容存档于26 May 2021）.

[FDA_PR_20210521-5] FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer. U.S. Food and Drug Administration (FDA) (新闻稿). 21 May 2021 [21 May 2021]. （原始内容存档于21 May 2021）. 本文含有此來源中屬於公有领域的内容。

[FDA_amivantamab-6] FDA grants accelerated approval to amivantamab-vmjw for mNSCLC. U.S. Food and Drug Administration (FDA). 21 May 2021 [21 May 2021]. （原始内容存档于22 May 2021）. 本文含有此來源中屬於公有领域的内容。

[Rybrevant_EPAR-7] Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. （原始内容存档于23 April 2022）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-8] 8.0 ^8.1 ^8.2 ^8.3 ^8.4 ^8.5 ^8.6 ^8.7 Rybrevant- amivantamab injection. DailyMed. Janssen Pharmaceutical Companies. [25 May 2021]. （原始内容存档于26 May 2021）.

[EPAR2022-9] 9.0 ^9.1 Rybrevant EPAR. European Medicines Agency (EMA). 12 October 2021 [23 April 2022]. （原始内容存档于23 April 2022）. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]

[3]

[7]

[4]

[5]

[6]

[8]

[9]